Treating nonthrombotic pulmonary hypertension from fibrosing mediastinitis
Part of Heart & circulation, Lungs & breathing clinical trials.
This study tests a treatment for a rare lung condition called fibrosing mediastinitis, where scar tissue in the chest presses on the lung artery, causing high blood pressure in the lungs. The goal is to see if the treatment can improve your symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with fibrosing mediastinitis between November 2024 and November 2026.
- You are between 18 and 85 years old.
- You have symptoms like chest tightness, shortness of breath, or trouble exercising.
- Your CT scan shows that enlarged lymph nodes in your chest are pressing on your lung artery, and you have high blood pressure in your lungs (pulmonary hypertension) that matches your symptoms.
- You can sign a consent form and are willing to follow the study plan and come back for checkups for one year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called sotatercept for people who have a specific type of high blood pressure in the lungs that happens along with heart failure with preserved ejection fraction (a stiff heart muscle). The treatment aims to improve your ability to be active and reduce symptoms, and the study will compare it to a placebo to see if it helps.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
This trial tests whether a new treatment made from menstrual blood stem cells, given by injection, can help people with IPF, a condition that causes lung scarring and makes breathing harder. The study aims to see if the treatment can slow down the disease and improve lung function.
This trial tests a treatment that reduces certain antibodies in your blood, which may help slow the progression of IPF. The treatment involves a procedure to filter your blood and then giving you antibodies to help your immune system.
This study tests whether starting an early anti-scarring medication can help people with stable lung fibrosis. It aims to see if the treatment slows down the disease and improves quality of life.
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.